| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director | CEO Level 15 +2 more
2 companies
Brett P Monia is Chief Executive Officer at IONS, with reported holdings spanning 2 companies. Brett P Monia's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $9.9M at current prices.
Our model assigns Brett P Monia a middling insider score of 63/100, based on 32 past trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of -13.1%.
Brett P Monia's largest disclosed position is in IONS as Chief Executive Officer, worth about $9.8M. The IONS filings lean toward selling, a net 923,101 shares.
Brett P Monia has 65 Form 4 filings on record from January 2019 to August 2026, across 2 companies: Chief Executive Officer at Ionis Pharmaceuticals (IONS), 2019–2026; Director at Cognition Therapeutics (CGTX), 2022–2026.
The 134 reported transactions were 47 open-market sales, 27 option exercises, 26 option or other derivative awards and 14 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 35 sales worth about $57.0M.
The largest open-market sale was 203,814 shares of IONS at an average $60.32 on September 3, 2025, about $12.3M. Twelve months later IONS was down 4%.
17 of the 24 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 7 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | IONS Ionis Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 85,637 | $79.70 | $6,825,523.71 | -25.9% | -46.0% | - | |
| May 14, 2026 | IONS Ionis Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 4,536 | $78.49 | $356,012.45 | -1.8% | -25.3% | - | |
| Mar 10, 2026 | IONS Ionis Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 160,773 | $75.35 | $12,114,155.20 | -39.9% | -2.8% | - | |
| Feb 6, 2026 | IONS Ionis Pharmaceuticals, Inc. | Chief Executive Officer | Sell10b5-1 | 29,430 | $85.79 | $2,524,820.30 | -10.4% | -12.1% | - | |
| Jan 30, 2026 | IONS Ionis Pharmaceuticals Inc | Chief Executive Officer | Sell | 62,970 | $82.72 | $5,208,979.15 | -18.2% | -9.6% | - | |
| Jan 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 44,034 | $74.82 | $3,294,623.88 | -16.4% | -1.4% | - | |
| Oct 6, 2025 | IONS Ionis Pharmaceuticals Inc | Chief Executive Officer | Sell10b5-1 | 437 | $69.26 | $30,268.24 | -0.2% | +13.8% | -36.3% | |
| Sep 3, 2025 | IONS Ionis Pharmaceuticals Inc | Chief Executive Officer | Sale+OE | 203,814 | $60.32 | $12,294,703.00 | -53.1% | +34.4% | -3.9% | |
| Jul 30, 2025 | IONS Ionis Pharmaceuticals Inc | Chief Executive Officer | Sale+OE10b5-1 | 2,432 | $45.00 | $109,440.00 | -1.3% | +69.6% | - | |
| Jul 11, 2025 | IONS Ionis Pharmaceuticals Inc | Chief Executive Officer | Sell10b5-1 | 1,160 | $41.74 | $48,416.20 | -0.6% | +68.4% | - |